{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T01:45:18Z","timestamp":1768441518570,"version":"3.49.0"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","jocn-journal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.jocn.2017.10.002","type":"journal-article","created":{"date-parts":[[2017,10,16]],"date-time":"2017-10-16T20:46:05Z","timestamp":1508186765000},"page":"228-233","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["A retrospective study of bevacizumab for treatment of brainstem glioma with malignant features"],"prefix":"10.1016","volume":"47","author":[{"given":"Shigeta","family":"Moriya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeo","family":"Ohba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhide","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuro","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Nagahisa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Kaito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Nakae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jocn.2017.10.002_b0005","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jocn.2017.10.002_b0010","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1093\/neuonc\/nor091","article-title":"A phase \u2161 trial of single-agent bevacizumab in patients with recurrent anaplastic glioma","volume":"13","author":"Kreisl","year":"2011","journal-title":"Neuro-Oncology"},{"issue":"10","key":"10.1016\/j.jocn.2017.10.002_b0015","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/jjco\/hys121","article-title":"Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma","volume":"42","author":"Nagane","year":"2012","journal-title":"Jpn J Oncol"},{"key":"10.1016\/j.jocn.2017.10.002_b0020","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.1002\/cncr.25462","article-title":"A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas","volume":"15","author":"Raizer","year":"2010","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.jocn.2017.10.002_b0025","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.jocn.2012.12.011","article-title":"Clinical characteristics and treatment of malignant brainstem gliomas in elderly patients","volume":"20","author":"Babu","year":"2013","journal-title":"J Clin Neurosci"},{"issue":"1","key":"10.1016\/j.jocn.2017.10.002_b0030","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1097\/MPH.0b013e318279aed8","article-title":"Prolonged survival after treatment of diffuse intrinsic pontine glioma with radiation, temozolamide, and bevacizumab","volume":"35","author":"Aguilera","year":"2013","journal-title":"J Pediatr Hematol Oncol"},{"issue":"1","key":"10.1016\/j.jocn.2017.10.002_b0035","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11060-015-2008-6","article-title":"A pilot study of bevacizumab-based therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas","volume":"127","author":"Hummel","year":"2016","journal-title":"J Neurooncol"},{"issue":"7","key":"10.1016\/j.jocn.2017.10.002_b0040","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3109\/08880018.2013.829895","article-title":"Treatment of children with diffuse intrinsic pontine gliomas with chemoradiotherapy followed by a combination of temozolomide, irinotecan, and bevacizumab","volume":"30","author":"Zaky","year":"2013","journal-title":"Pediatr Hematol Oncol"},{"issue":"18","key":"10.1016\/j.jocn.2017.10.002_b0045","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/JCO.2009.26.8789","article-title":"Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a pediatric brain tumor consortium study","volume":"28","author":"Gururangan","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jocn.2017.10.002_b0050","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.clineuro.2012.04.027","article-title":"Bevacizumab as salvage therapy for progressive brain stem gliomas","volume":"115","author":"Reithmeier","year":"2013","journal-title":"Clin Neurol Neurosurg"},{"issue":"2","key":"10.1016\/j.jocn.2017.10.002_b0055","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s11060-014-1571-6","article-title":"Bevacizumab-related toxicities in the National Cancer Institute malignant glioma trial cohort","volume":"120","author":"Odia","year":"2014","journal-title":"J Neurooncol"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586817314455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586817314455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T16:34:12Z","timestamp":1541090052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586817314455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":11,"alternative-id":["S0967586817314455"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2017.10.002","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A retrospective study of bevacizumab for treatment of brainstem glioma with malignant features","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2017.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}